VISEN PHARMA-B (02561) has a current Price-to-Book (P/B) ratio of 3.76. Compared to its 3-year average P/B ratio of 2.86, the current P/B ratio is approximately 31.30% higher. Relative to its 5-year average P/B ratio of 2.86, the current P/B ratio is about 31.30% higher. VISEN PHARMA-B (02561) has a Forward Free Cash Flow (FCF) yield of approximately -5.69%. Compared to its 3-year average FCF yield of -4.29%, the current FCF yield is approximately 32.55% lower. Relative to its 5-year average FCF yield of -4.29%, the current FCF yield is about 32.55% lower.

Performance Decomposition

AI Analysis

Market capitalization of 02561 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 02561 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 02561 currently overvalued or undervalued?

What is VISEN PHARMA-B (02561) fair value?

02561's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of VISEN PHARMA-B (02561) is between to according to relative valuation method.

How does 02561's valuation metrics compare to the industry average?

The average P/S ratio for 02561's competitors is 0.00, providing a benchmark for relative valuation. VISEN PHARMA-B Corp (02561) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for VISEN PHARMA-B (02561) as of Mar 03 2026?

As of Mar 03 2026, VISEN PHARMA-B (02561) has a P/B ratio of 3.76. This indicates that the market values 02561 at 3.76 times its book value.

What is the current FCF Yield for VISEN PHARMA-B (02561) as of Mar 03 2026?

As of Mar 03 2026, VISEN PHARMA-B (02561) has a FCF Yield of -5.69%. This means that for every dollar of VISEN PHARMA-B's market capitalization, the company generates -5.69 cents in free cash flow.

What is the current Forward P/E ratio for VISEN PHARMA-B (02561) as of Mar 03 2026?

As of Mar 03 2026, VISEN PHARMA-B (02561) has a Forward P/E ratio of -11.58. This means the market is willing to pay $-11.58 for every dollar of VISEN PHARMA-B's expected earnings over the next 12 months.

What is the current Forward P/S ratio for VISEN PHARMA-B (02561) as of Mar 03 2026?

As of Mar 03 2026, VISEN PHARMA-B (02561) has a Forward P/S ratio of 30.97. This means the market is valuing 02561 at $30.97 for every dollar of expected revenue over the next 12 months.

02561 Valuation